Volume 30, Issue 142 (September & October 2022)                   J Adv Med Biomed Res 2022, 30(142): 452-457 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kaffashian M, Hadavi M, Taghinezhad F, Ahmadi I, Tahmasebi Ghorabi S, Khalafzadeh A et al . A Retrospective Cohort Study of SARS-CoV-2 Mortality Rate in Individuals with Opioid Use Disorder in Ilam (Southwest of Iran). J Adv Med Biomed Res 2022; 30 (142) :452-457
URL: http://journal.zums.ac.ir/article-1-6569-en.html
1- Dept. of Physiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran
2- Dept. of Internal Medicine, School of Medicine, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran
3- Clinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran
4- Clinical Research Development Unit, Imam Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran
5- Non-Communicable Diseases Center, Ilam University of Medical Sciences, Ilam, Iran , amozafari99@yahoo.com
Abstract:   (46568 Views)

Background and Objective: Individuals with opioid use disorder are a marginalized population in any society. They commonly have a weaker immune system, greater stress vulnerability, poorer health, more high-risk behaviors, and less access to healthcare services compared to the general population, which can expose them to a risk of severe COVID-19 complications. This study aimed to evaluate the effects of opioid use disorder on mortality in patients with SARS-CoV-2.
Materials and Methods: This registry-based retrospective cohort study was conducted on 2362 consecutive inpatients with a confirmed diagnosis of SARS-CoV-2 between March 5, 2020 and March 21, 2021, presenting to a university hospital in Ilam in the southwest of Iran. Forty-five patients with opioid use disorder were identified in this study and matched to 100 patients without opium addiction. All patients with a history of opium addiction were included in the study group, and age- and sex-matched patients without opioid use disorder were randomly recruited as the controls. After adjusting for the effects of age and comorbidities, data were analyzed in STATA version 10, using logistic regression models.
Results: The mortality of patients with opioid use disorder increased following COVID-19 (adjusted OR: 6.59; 95% CI: 1.84–23.59; P=0.004). Hypertension (adjusted OR: 8.17; 95% CI: 2.21–30.15; P=0.002) and advancing age (OR: 1.06; 95% CI: 1.01–1.11; P=0.01) were significantly associated with increased COVID-19 mortality.
Conclusion: Based on the present findings, opioid use disorder is a possible risk factor for mortality following COVID-19. The findings of the present study can be applied in the implementation of preventive measures and policies and prioritization of COVID-19 vaccination. However, further relevant research is recommended.

Full-Text [PDF 288 kb]   (24452 Downloads) |   |   Full-Text (HTML)  (878 Views)  

 Based on the present findings, opioid use disorder is a possible risk factor for mortality following COVID-19. The findings of the present study can be applied in the implementation of preventive measures and policies and prioritization of COVID-19 vaccination. However, further relevant research is recommended.


Type of Study: Original Article | Subject: Epidemiologic studies
Received: 2021/05/27 | Accepted: 2021/10/3 | Published: 2022/08/8

References
1. Yang P, Wang X. COVID-19: a new challenge for human beings. Cell Molec Immunol. 2020;17(5):555-7. [DOI:10.1038/s41423-020-0407-x] [PMID] [PMCID]
2. Adil MT, Rahman R, Whitelaw D, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgraduate Med J. 2021;97(1144):110-6. [DOI:10.1136/postgradmedj-2020-138386] [PMID]
3. Organization WH. Coronavirus disease (‎ COVID-19)‎ outbreak: rights, roles, and responsibilities of health workers, including key considerations for occupational safety and health: interim guidance, March 19, 2020. World Health Organization; 2020.
4. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Rev Endocrinol. 2020:1-20. [DOI:10.1038/s41574-020-00435-4] [PMID] [PMCID]
5. Qeadan F, Tingey B, Bern R, et al. Opioid use disorder and health service utilization among COVID-19 patients in the US: A nationwide cohort from the Cerner Real-World Data. e Clin Med. 2021:100938. [DOI:10.1016/j.eclinm.2021.100938] [PMID] [PMCID]
6. Bahorik AL, Satre DD, Kline-Simon AH, Weisner CM, Campbell CI. Alcohol, cannabis, and opioid use disorders, and disease burden in an integrated healthcare system. J Addict Med. 2017;11(1):3. [DOI:10.1097/ADM.0000000000000260] [PMID] [PMCID]
7. James A, Williams J. Basic opioid pharmacology-an update. Br J Pain. 2020;14(2):115-21. [DOI:10.1177/2049463720911986] [PMID] [PMCID]
8. Pirnia B, Dezhakam H, Pirnia K, et al. COVID-19 pandemic and addiction: Current problems in Iran. Asian J Psychiatr. 2020;54:102313. [DOI:10.1016/j.ajp.2020.102313] [PMID] [PMCID]
9. Kahnouji M, Forud A, Homaie S, Naghibzadeh-Tahami A. Is the urinary morphine concentration a useful marker for the assessment of the severity of coronary artery stenosis in opium addicts? Iran Heart J. 2019;20(4):64-70.
10. Farhoudian A, Baldacchino A, Clark N, et al. COVID-19 and substance use disorders: Recommendations to a comprehensive healthcare response. An international society of addiction medicine practice and policy interest group position paper. Basic Clin Neurosci. 2020;11(2):133. [DOI:10.32598/bcn.11.covid19.1] [PMID] [PMCID]
11. Salmond S, Allread V. A population health approach to America's opioid epidemic. Orthoped Nurs. 2019;38(2):95. [DOI:10.1097/NOR.0000000000000521] [PMID] [PMCID]
12. Nakhaee S, Ghasemi S, Karimzadeh K, Zamani N, Alinejad-Mofrad S, Mehrpour O. The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms. Subst Abuse Treat Prev Policy. 2020;15(1):1-13. [DOI:10.1186/s13011-020-00272-8] [PMID] [PMCID]
13. Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes Metab Syndr. 2020;14(5):817-23. [DOI:10.1016/j.dsx.2020.06.008] [PMID] [PMCID]
14. Jadoo SAA. COVID-19 pandemic is a worldwide typical biopsychosocial crisis. J Idea Health. 2020;3(2):152-4. [DOI:10.47108/jidhealth.Vol3.Iss2.58]
15. Yanez ND, Weiss NS, Romand J-A, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1-7. [DOI:10.1186/s12889-020-09826-8] [PMID] [PMCID]
16. Sacerdote P. Opioids and the immune system. Palliative Med. 2006;20(8_suppl):9-15. [DOI:10.1191/0269216306pm1124oa]
17. Moyano J, Aguirre L. Opioids in the immune system: from experimental studies to clinical practice. Revista da Associação Médica Brasileira. 2019;65:262-9. [DOI:10.1590/1806-9282.65.2.262] [PMID]
18. Ataei M, Shirazi FM, Lamartine RJ, Nakhaee S, Mehrpour O. A double-edged sword of using opioids and COVID-19: a toxicological view. Subst Abuse Treat Prev Policy. 2020;15(1):1-4. [DOI:10.1186/s13011-020-00333-y] [PMID] [PMCID]
19. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Molec Psychiatr. 2021;26(1):30-9. [DOI:10.1038/s41380-020-00895-0] [PMID] [PMCID]
20. Mehta S, Parmar N, Kelleher M, et al. COPD and asthma in patients with opioid dependency: a cross-sectional study in primary care. NPJ Prim Care Respir Med. 2020;30(1):1-6. [DOI:10.1038/s41533-019-0161-7] [PMID] [PMCID]
21. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Rev Cardiol. 2020;17(9):543-58. [DOI:10.1038/s41569-020-0413-9] [PMID] [PMCID]
22. Khatri UG, Perrone J. Opioid use disorder and COVID-19: crashing of the crises. J Addict Med. 2020. 14(4):e6-e7 [DOI:10.1097/ADM.0000000000000684] [PMID] [PMCID]
23. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Europ Respirat J. 2016;48(3):683-93. [DOI:10.1183/13993003.01967-2015] [PMID]
24. Volkow N. COVID-19: potential implications for individuals with substance use disorders. Sci Am. 2020.

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb